news
HHS Legal Chief Matt Zorn Outlines Federal Path for Ibogaine Access
At the Psychedelic Healthcare Forum in New York, HHS Deputy General Counsel Matt Zorn gave his first public interview on federal psychedelic policy. Zorn addressed how Right to Try pathways and potential executive actions could bypass traditional scheduling delays for ibogaine. The signal points toward direct federal engagement with plant medicines for severe addiction.
At the Psychedelic Healthcare Forum in New York, HHS Deputy General Counsel Matt Zorn gave his first public interview on federal psychedelic policy. Zorn addressed how Right to Try pathways and potential executive actions could bypass traditional scheduling delays for ibogaine. The signal points toward direct federal engagement with plant medicines for severe addiction.
The architecture take
I spent years watching drug policy attorneys spar with federal agencies, but seeing Matt Zorn sit inside HHS changes the math entirely. Zorn made his name suing the DEA over scheduling bottlenecks. Now he advises the federal government, talking openly about using Right to Try laws and executive orders to carve out lanes for ibogaine. For severe opioid dependence and treatment-resistant trauma, ibogaine resets dopamine signaling and interrupts acute withdrawal in a single session. That matters. It also carries cardiac liabilities through hERG channel inhibition, which has long paralyzed traditional approvals. Zorn essentially signaled that HHS might treat end-stage substance use disorder with the urgency of terminal oncology rather than waiting a decade for synthetic analogs to finish trials. I admit I doubted the feds would move first. If Right to Try opens the door, state-funded clinics in Ohio and Kentucky will get cover to treat patients without fearing federal raids (a wild shift from five years ago).